North Carolina is currently home to 2644 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Durham, Charlotte, Winston-Salem and Chapel Hill. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection
NCT06672055
Recruiting
The primary objective of the study is to determine the relative efficacy of the investigational oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine tablet VXA-CoV2-3.3 compared to a currently recommended vaccine for the prevention of symptomatic Coronavirus Disease 2019 (COVID-19). In order to represent a more recently circulating SARS-CoV-2 variant, the main study endpoints will now evaluate the VXA-CoV2-3.3 (KP.2 strain) vaccine, and not the VXA-CoV2-3.1 (XBB.1.5 strain)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: Cary Medical Group, Cary, North Carolina
Conditions: SARS-CoV2, COVID-19
Register for Updates
Glycogen Storage Disease Type Ia (GSDIa) Disease Monitoring Program
NCT06636383
Recruiting
The main objective of this observational study is to evaluate the long-term safety and effectiveness of DTX401 for at least 10 years after DTX401 administration.
Gender:
ALL
Ages:
2 years and above
Trial Updated:
06/03/2025
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Glycogen Storage Disease Type Ia
Register for Updates
Time Restricted Eating (TRE) in Metastatic Head and Neck Squamous Cell Cancer (mHNSCC)
NCT06603155
Recruiting
The purpose of this study is to evaluate whether Time Restricted Eating (TRE) can improve responses in participants with metastatic head and neck squamous cell cancer (mHNSCC) receiving Immune Checkpoint Blockers (ICB) by changing the gut microbiome (the bacteria and other microorganisms living in individual's bodies). A particular focus of this study is to compare the outcomes of African American participants when compared to the rest of the participant population. TRE is a form of intermittent... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: Duke Cancer Center, Durham, North Carolina
Conditions: Metastatic Head-and-neck Squamous-cell Carcinoma
Register for Updates
Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML
NCT06580106
Recruiting
The purpose of this research is to see how certain genetic variations relate to side effects and outcomes experienced while receiving treatment with azacitidine and venetoclax.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: Levine Cancer Institute, Charlotte, North Carolina
Conditions: Leukemia, Myeloid, Acute
Register for Updates
Optimization of Pediatric Tonsillectomy to IMprove AnaLgesia
NCT06576830
Recruiting
The purpose of this study is to compare the use of short acting opioids (fentanyl/hydromorphone) with long acting opioids (methadone) for pain control following tonsillectomy surgery in children and adolescents.
Gender:
ALL
Ages:
Between 3 years and 17 years
Trial Updated:
06/03/2025
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Pain, Postoperative, Tonsillar Hypertrophy, Tonsillitis, Pediatric Sleep Apnea, Sleep-Disordered Breathing
Register for Updates
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT06568939
Recruiting
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to assess how safe telisotuzumab vedotin is in adult participants with NSCLC. Change in disease activity and adverse events will be assessed. Telisotuzumab vedotin is an investigational drug being developed for the treatment of NSCLC. Participants will be... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: FirstHealth of the Carolinas- Speciality Center /ID# 272924, Pinehurst, North Carolina
Conditions: Non-Small Cell Lung Cancer
Register for Updates
A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis
NCT06559150
Recruiting
This study is a randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of ensifentrine inhalation suspension (3 mg) delivered twice daily via standard jet nebulizer over at least 24 weeks, compared to placebo, in subjects with non-cystic fibrosis bronchiectasis (NCFBE).
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
06/03/2025
Locations: University of North Carolina, Chapel Hill, North Carolina
Conditions: Non-cystic Fibrosis Bronchiectasis
Register for Updates
A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes
NCT06542874
Recruiting
The study will look at how well different doses of a new medicine called NNC0487-0111 help lower the blood sugar and body weight in people with type 2 diabetes. NNC0487-0111 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Participants will either get NNC0487-0111, which is given as tablets or as injections, or placebo. Which treatment the participant get is decided by chance.The study will last for about 43 weeks.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/03/2025
Locations: Lucas Research Inc., Morehead City, North Carolina
Conditions: Type 2 Diabetes (T2D)
Register for Updates
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 75 Years With gMG.
NCT06517758
Recruiting
The study is a randomized, double-blind, placebo-controlled, multicenter, Phase III study, to evaluate efficacy, safety and tolerability of iptacopan in patients with AChR+ gMG who are on stable SOC treatment. Participants who meet the eligibility criteria will be randomized in a ratio of 1:1, to receive either iptacopan or matching placebo, for 6 months (180 days) while continuing on a stable SOC treatment. The randomization will be stratified based on region.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/03/2025
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Generalized Myasthenia Gravis
Register for Updates
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06497556
Recruiting
The purpose of this study is to assess the safety and efficacy of divarasib compared to locally approved KRAS G12C inhibitors (sotorasib or adagrasib) in participants with KRAS G12C-positive (KRAS G12C +) advanced or metastatic non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: University of North Carolina At Chapel Hill, Chapel Hill, North Carolina
Conditions: Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
Register for Updates
Evaluation of a Simple-Prep Controlled Embolic
NCT06453642
Recruiting
The objective of this study is to evaluate the safety and effectiveness of the GPX® Embolic Device when used as indicated for embolization requiring distal vessel penetration in 114 subjects in up to 25 investigational sites in the USA, New Zealand, and Canada.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: University of North Carolina, Chapel Hill, North Carolina
Conditions: Vascular Tumor, Renal Angiomyolipoma, Renal Cell Carcinoma, Bone Tumor, Embolization, Portal Vein Embolization
Register for Updates
Assessing Better Bottles for Babies
NCT06357299
Recruiting
This study will use a 2 x 2 factorial design to test impact of two intervention strategies (bottle size and bottle opacity) on infant weight gain.
Gender:
ALL
Ages:
Between 3 days and 1 month
Trial Updated:
06/03/2025
Locations: Duke University, Durham, North Carolina
Conditions: Pediatric Obesity, Weight Gain Trajectory, Infant Obesity
Register for Updates